More articles from Targeting Drug Resistance: Poster Presentations - Proffered Abstracts

Abstract B50: Preclinical efficacy of combined MEK and Src inhibition: MEK inhibitor reverses resistance to Src inhibitor therapy in ovarian cancer cells
Fiona Simpkins, Diana Azzam, Joyce M. Slingerland

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B50; DOI: 10.1158/1078-0432.OVCA13-B50
Abstract B48: Targeting chemo-resistance in CCNE1-amplified ovarian cancer
Barbie Taylor-Harding, Hasmik Agadjanian, Paul Joseph Aspuria, Takako Mizuno, Dong-Joo Cheon, Sandra Orsulic, Beth Karlan, Christine Walsh, Wolf Ruprecht Wiedemeyer

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B48; DOI: 10.1158/1078-0432.OVCA13-B48
Abstract B52: The bromodomain inhibitor JQ1 enhances cisplatin-mediated cytotoxicity in ovarian cancer cells
Dineo Khabele, Andrew J. Wilson, Jeanette Saskowski, Scott W. Hiebert

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B52; DOI: 10.1158/1078-0432.OVCA13-B52
Abstract B51: Management of ascites via the alfa-pump closed system in platinum-resistant-ovarian-cancer (PROC): A model of sequential non-invasive tumor-cell sampling through the urinary bladder
Christina Fotopoulou, Laura Spiers, Delali Adjogatse, Emily Pickford, Roberto Dina, Sara Blagden, Nagy Habib, Hani Gabra

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B51; DOI: 10.1158/1078-0432.OVCA13-B51
Abstract B49: The role of oxidative stress in the development of cisplatin resistance in epithelial ovarian cancer
Jimmy Belotte, Nicole Fletcher, Awoniyi Awonuga, Mitchell Alexis, Husam Abu-soud, Michael Diamond, Mohammed Saed, Ghassan Saed

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B49; DOI: 10.1158/1078-0432.OVCA13-B49
Abstract B44: Mapping, targeting, and eliminating therapeutically unresponsive ovarian cancer with high content imaging and photodynamic therapy
Hsin-I Hung, Oliver J. Klein, Yookyung Jung, Kashmira S. Kulkarni, Bo R. Rueda, Rosemary Foster, Conor L. Evans

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B44; DOI: 10.1158/1078-0432.OVCA13-B44
Abstract B32: The role of the glucocorticoid receptor (GR) in inhibiting chemotherapy-induced apoptosis in high-grade serous ovarian carcinoma (HGS-OvCa)
Erica M. Stringer, Maxell N. Skor, Lei Zhao, Katja Gwin, Ernst Lengyel, Gini F. Fleming, Suzanne D. Conzen

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B32; DOI: 10.1158/1078-0432.OVCA13-B32
Abstract A53: Biomarkers of chemotherapy resistance in serous epithelial ovarian cancer identified by integrative genomic and transcriptomic analysis
Madhuri Koti, Robert J. Gooding, Paulo Nuin, Alexandria Haslehurst, Colleen Crane, Johanne Weberpals, Timothy Chids, Peter Bryson, Moyez Dharsee, Kenneth R. Evans, Harriet E. Feilotter, Paul C. Park, Jeremy A. Squire

Clinical Cancer Research Oct 2013, 19 (19 Supplement) A53; DOI: 10.1158/1078-0432.OVCA13-A53
Abstract B40: MiR-30c-2-3p participates in a regulatory feedback loop to inhibit the progression of chemoresistant ovarian cancer cells
Mandi Murph, Wei JIa, Molly Altman, Ha Nguyen

Clinical Cancer Research Oct 2013, 19 (19 Supplement) B40; DOI: 10.1158/1078-0432.OVCA13-B40
Abstract A49: Adipocytes promote ovarian cancer cell chemoresistance
Jiang Yang, Marsha A. Moses

Clinical Cancer Research Oct 2013, 19 (19 Supplement) A49; DOI: 10.1158/1078-0432.OVCA13-A49

Main menu

User menu

Search

More articles from Targeting Drug Resistance: Poster Presentations - Proffered Abstracts

Pages

Articles

Info for

About Clinical Cancer Research